Related Experiment Videos
Cardiovascular risk in patients with treated familial hypercholesterolaemia and patients with severe
Insights
This study investigated ischaemic heart disease (IHD) in patients with familial hypercholesterolaemia (FH) and severe hypertriglyceridaemia. Findings indicate IHD evidence in FH and hypertriglyceridaemia patients, with lower mortality in FH possibly due to improved cholesterol management.
Area of Science:
- Cardiology
- Genetics
- Metabolic Disorders
Background:
- Familial hypercholesterolaemia (FH) is a genetic disorder causing high LDL cholesterol.
- Severe hypertriglyceridaemia is associated with increased cardiovascular risk.
- Ischaemic heart disease (IHD) poses a significant health burden.
Purpose of the Study:
- To assess IHD morbidity and mortality in patients with heterozygous FH and severe hypertriglyceridaemia.
- To compare current IHD outcomes in FH patients with historical data.
- To explore factors influencing IHD mortality in these patient groups.
Main Methods:
- Retrospective analysis of 76 patients with heterozygous FH and 18 patients with severe hypertriglyceridaemia.
- Assessment of IHD evidence through medical records.
- Follow-up over a mean period of 5.5 years to determine mortality.
Main Results:
- IHD evidence was found in 38% of FH patients and 44% of hypertriglyceridaemia patients.
- Two deaths occurred in the hypertriglyceridaemia group; no deaths were recorded in the FH group.
- The observed low mortality in FH patients contrasts with previous reports.
Conclusions:
- Patients with heterozygous FH and severe hypertriglyceridaemia exhibit significant IHD morbidity.
- Improved management strategies may have contributed to reduced mortality in FH patients.
- Further research is warranted to confirm the impact of contemporary treatments on IHD outcomes in these conditions.
Abstract:
A study was performed to determine the morbidity and mortality from ischaemic heart disease (IHD) in patients with heterozygous familial hypercholesterolaemia (FH) and severe hypertriglyceridaemia (pretreatment plasma triglyceride greater than 5 mmol/l). Twenty-nine (38%) of 76 patients with FH and 8(44%) of 18 patients with hypertriglyceridaemia had evidence of IHD. Over a mean follow-up period of 5.5 years, 2 patients with hypertriglyceridaemia died but there were no deaths in patients with FH. This contrasts with earlier reports which showed a high mortality in FH patients. The lower mortality may be due to improved treatment and consequent lower levels of cholesterol.